Trial
NCT06655818
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Relapsed/Refractory Multiple Myeloma
Intervention
Belantamab Mafodotin
Why stopped
The study was terminated due to lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-03